期刊
CLINICAL INFECTIOUS DISEASES
卷 54, 期 -, 页码 S79-S85出版社
OXFORD UNIV PRESS INC
DOI: 10.1093/cid/cir886
关键词
-
资金
- National Institutes of Health through MD Anderson's Cancer Center [CA016672]
- Henry Schueler 419 Foundation
- Merck Co
- Gilead
- Astellas
- Enzon
- Novartis
- Merck
- Pfizer
- NovaDigm Therapeutics
- Schering-Plough
- Aventis
- MSD
Mucormycosis has emerged as an important opportunistic infection, especially in severely immunosuppressed hosts. The evolving epidemiology, immunopathogenesis, molecular virulence studies, early diagnosis, and pitfalls in designing clinical studies of mucormycosis are discussed in this article.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据